

Lucemyra® (lofexidine) - First-time generic

- On August 21, 2024, <u>Indoco Remedies launched</u> an <u>AB-rated</u> generic version of US WorldMeds' Lucemyra (lofexidine) tablets.
 - Indoco Remedies was granted 180-days of Competitive Generic Therapy exclusivity for generic Lucemyra.
- Lucemyra is approved for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
- According to IQVIA[™], Lucemyra had U.S. annual sales of \$15.6 million.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.